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OBJECTIVES We sought to determine the outcomes of patients with cardiogenic shock (CS) complicating
non-ST-segment elevation acute myocardial infarction (MI).
BACKGROUND Such patients represent a high-risk (ST-segment depression) or low-risk (normal or
nonspecific electrocardiographic findings) group for whom optimal therapy, particularly in the
setting of shock, is unknown.
METHODS We assessed characteristics and outcomes of 881 patients with CS due to predominant left
ventricular (LV) dysfunction in the SHOCK Trial Registry.
RESULTS Patients with non-ST-segment elevation MI (n 5 152) were significantly older and had
significantly more prior MI, heart failure, azotemia, bypass surgery, and peripheral vascular
disease than patients with ST-elevation MI (n 5 729). On average, the groups had similar
in-hospital LV ejection fractions (;30%), but patients with non-ST-elevation MI had a
lower highest creatine kinase and were more likely to have triple-vessel disease. Among
patients selected for coronary angiography, the left circumflex artery was the culprit vessel in
34.6% of non-ST-elevation versus 13.4% of ST-elevation MI patients (p 5 0.001). Despite
having more recurrent ischemia (25.7% vs. 17.4%, p 5 0.058), non-ST-elevation patients
underwent angiography less often (52.6% vs. 64.1%, p 5 0.010). The proportion undergoing
revascularization was similar (36.8% for non-ST-elevation vs. 41.9% ST-elevation MI, p 5
0.277). In-hospital mortality also was similar in the two groups (62.5% for non-ST-elevation
vs. 60.4% ST-elevation MI). After adjustment, ST-segment elevation MI did not indepen-
dently predict in-hospital mortality (odds ratio, 1.30; 95% confidence interval, 0.83 to 2.02;
p 5 0.252).
CONCLUSIONS Patients with CS and non-ST-segment elevation MI have a higher-risk profile than shock
patients with ST-segment elevation, but similar in-hospital mortality. More recurrent
ischemia and less angiography represent opportunities for earlier intervention, and early
reperfusion therapy for circumflex artery occlusion should be considered when non-ST-
elevation MI causes CS. (J Am Coll Cardiol 2000;36:1091–6) © 2000 by the American
College of Cardiology
The first large, randomized trials of fibrinolytic therapy for
acute myocardial infarction (MI), which included patients
with any electrocardiographic (ECG) findings, observed
that the prognosis differed with the presence or absence of
ST-segment elevation. Patients with ST-segment depres-
sion MIs were at higher risk of early mortality, whereas
patients with a normal ECG or nonspecific ECG findings
were at lower risk (1–6). Moreover, although there is
substantial evidence for a benefit of reperfusion therapy for
MI patients with ST-segment elevation (1,7), the best
treatment strategy for patients with non-ST-segment ele-
vation MI is less well-defined (8). Similarly, the role of early
revascularization for ST-segment elevation MI complicated
by cardiogenic shock (CS) has been studied in a randomized
clinical trial (9), but the optimal therapy of non-ST-
segment elevation MI when CS develops is unknown.
In an international CS registry, patients with primary left
ventricular (LV) failure associated with ST-segment depres-
sion, T-wave inversion, or previous left bundle branch block
(LBBB) were older, developed shock later, and were less
likely to undergo coronary angiography and early revascu-
larization, compared with patients who had ST-segment
elevation (10). In this small cohort study, the mortality in
the two groups was similar. To further evaluate the char-
acteristics of patients with non-ST-segment elevation MI
complicated by CS shock and to determine whether the
absence of ST-segment elevation is a predictor of in-
hospital mortality, we compared MI patients with and
without ST-segment elevation in a large registry associ-
ated with the SHould we emergently revascularize Oc-
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cluded coronaries for Cardiogenic shocK? (SHOCK)
Trial.
METHODS
SHOCK Trial Registry. The SHOCK Trial was a ran-
domized comparison of early percutaneous or surgical re-
vascularization versus initial medical stabilization (including
thrombolytic therapy and intra-aortic balloon pumping,
where appropriate) for patients with acute MI complicated
by CS (9). Patients with suspected CS, either ineligible for
participation or eligible but not randomized, were entered
into a registry that is described in this supplementary issue
of the Journal (11). The institutional committee on human
research approved the study protocol at each center.
Patient sample. This report is based on 881 patients with
CS due to primary LV failure, a subset of the 1,190 patients
with CS complicating acute MI who were prospectively
registered. Of 1,190 patients, five were excluded from this
report because of missing ECG data. Of the remaining
1,185 patients, 304 patients had CS due to mechanical
complications, cardiac tamponade, a cardiac catheterization
laboratory complication, isolated right ventricular dysfunc-
tion, severe valvular heart disease, pharmacologic therapy
(beta- or calcium-blocking agents) or noncardiac causes,
and they were also excluded. The remaining 881 patients
comprised the study group and included 152 patients
(17.3%) without ST-segment elevation and 729 patients
(82.7%) with ST-segment elevation.
Definitions. ST-segment elevation MI was defined by the
presence of at least one of the following: at least two ECG
leads with new ST-segment elevation, new Q waves in at
least two leads, posterior ST-segment elevation (anterior
ST-segment depression in leads V2 or V3 with R/S . 1),
posterior Q waves or new LBBB. Non-ST-segment eleva-
tion MI was defined by the absence of all of the above
criteria. Predominant LV failure was designated as the
etiology of CS when no other major shock categories
(previously described [11]) were present. Creatine kinase
(CK) values reported are the highest recorded (based on
three or more measures for 71% of patients).
Data collection. Data were abstracted from the medical
record by the SHOCK study coordinators, who were
centrally trained to complete standard study-report forms.
Patient characteristics, MI characteristics, hemodynamics,
procedure use and vital status at discharge were recorded.
Cardiac catheterization and angioplasty reports were sent to
the clinical Coordinating Center for abstraction and com-
pletion of the standard form. Among patients with predom-
inant LV failure included in this analysis, right-heart
catheterization was performed in 567 patients with pulmo-
nary capillary wedge pressure recorded in 532 and cardiac
index in 405 patients. Left ventricular ejection fraction was
measured during hospitalization on the same day as, or
post-shock, by LV angiography (36%), echocardiography
(59%), or gated blood-pool scan (5%) in 299 patients. The
following variables were available on a maximum 632
patients: ejection fraction, pulmonary artery pressures, his-
tory of elevated lipids, peripheral vascular disease, recur-
rence of ischemic events and re-infarction.
Statistical analysis. We compared patients with non-ST-
segment elevation and ST-segment elevation MI using the
Fisher exact test for categorical variables, the Wilcoxon
rank-sum test for ordinal and non-normally distributed
continuous variables, and the Student t-test for normally
distributed continuous variables. For comparison of ordered
angiographic variables (stenosis and coronary flow catego-
ries), the Mantel-Haenszel test for linear trends was used.
In-hospital mortality by groups was analyzed using logistic
regression. To determine whether ST-segment elevation
(vs. non-ST-segment elevation) was an independent predic-
tor of in-hospital mortality, we constructed a multivariate
model adjusting for patient and treatment differences. All
variables that were collected on the overall cohort (right
heart catheterization, hemodynamic values, and angio-
graphic findings were excluded) and that had a univariate p
value ,20.20 in univariate group comparison were evaluated.
All variables with a final p value ,20.05 were retained in the
model. All analyses were conducted using SAS (SAS
Institute, Cary, North Carolina).
RESULTS
Clinical characteristics. Patients with non-ST-segment
elevation MI were significantly older than patients with
ST-segment elevation (Table 1). Gender was not associated
with non-ST-segment elevation (36% female overall), and
there was a similar proportion with prior hypertension,
diabetes mellitus, smoking and hyperlipidemia in the two
groups. Of note, there were significantly higher rates of
prior MI, congestive heart failure (CHF), renal insuffi-
ciency, prior bypass surgery and peripheral vascular disease
in patients with non-ST-segment elevation MI.
The median times from the index MI to the diagnosis of
CS did not differ significantly between patients with non-
ST-segment elevation (8.9 h) and those with ST-segment
elevation MI (5.8 h) (Table 2). However, the highest CK
(median 1,034 IU/L vs. 2,209 IU/L) and ratio of highest
CK to the upper limit of normal (median 4.8 vs. 10.6) were
significantly lower in the non-ST-segment elevation group.
Abbreviations and Acronyms
CHF 5 congestive heart failure
CK(-MB) 5 creatine kinase (-MB)
CS 5 cardiogenic shock
ECG 5 electrocardiogram, electrocardiographic
LBBB 5 left bundle branch block
LV 5 left ventricular, left ventricle
MI 5 myocardial infarction
SHOCK 5 SHould we emergently revascularize
Occluded Coronaries for cardiogenic
shocK?
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Of these two groups, 3.3% and 40.9%, respectively, received
thrombolytic therapy. Of note, in a small subset of patients
in whom LV function was measured after the diagnosis of
shock, LV ejection fraction was similar between groups.
Hemodynamic characteristics. The mean heart rates and
systolic and diastolic blood pressures did not differ between
groups (Table 3). Similarly, in the subset of patients
undergoing right-heart catheterization, there was no signif-
icant difference between groups in cardiac output, cardiac
index or pulmonary capillary wedge pressure.
Angiographic characteristics. Overall, 52.6% of patients
with non-ST-segment elevation and 64.1% of patients with
ST-segment elevation MI underwent coronary angiography
(p 5 0.010). After the onset of CS, the rate of angiography
in the non-ST-segment elevation group (40.8%) was lower
than that in the ST-segment elevation group (51.5%) (p 5
0.020). The severity of coronary disease in patients under-
going coronary angiography is shown in Figure 1. Patients
with non-ST-segment elevation MI had zero to single-
vessel disease less often than did patients with ST-segment
elevation (6.9% vs. 24.8%), with a corresponding increase in
triple-vessel disease (76.7% vs. 53.5%), p 5 0.001. The
prevalence of left main disease was also greater in patients
with non-ST-segment elevation MI (26.4% vs. 14.3%, p 5
0.014).
The culprit artery stenosis responsible for the index MI
differed between groups (Table 4). The circumflex was the
culprit artery significantly more often in patients with
non-ST-segment elevation MI (34.6% vs. 13.4%, p 5
Figure 1. Severity of coronary vessel disease in patients with shock due to
LV failure undergoing coronary angiography. No or single-, double-,
triple-vessel disease: n 5 73 for non-ST-segment elevation and n 5 443
for ST-segment elevation MI; left main disease: n 5 72 for non-ST-
segment elevation and n 5 434 for ST-segment elevation MI.
Table 1. Characteristics of Patients With CS Due to
Predominant LV Failure
Non-ST-segment
Elevation
(n 5 152)
ST-segment
Elevation
(n 5 729) p Value
Age (yrs) 71.4 6 11.0 67.9 6 12.2 , 0.001
Male gender 65.1% 63.4% 0.712
History of hypertension 57.1% 50.4% 0.147
Diabetes 31.3% 33.2% 0.703
Cigarette smoking 49.6% 51.9% 0.697
History of elevated lipids
(n 5 83, 359)
42.2% 39.6% 0.710
History of myocardial
infarction
55.7% 36.7% , 0.001
Congestive heart failure 35.2% 16.5% , 0.001
History of renal
insufficiency
20.7% 8.4% , 0.001
History of bypass surgery 18.5% 8.4% , 0.001
History of peripheral
vascular disease
(n 5 102, 457)
28.4% 16.4% 0.007
Other disease* 18.9% 17.4% 0.636
Data presented are mean 6 SD or percentages. *Life-shortening, noncardiac disease.
Table 2. Characteristics of MI
Non-ST-segment
Elevation
(n 5 152)
ST-segment
Elevation
(n 5 729) p Value
Time from MI onset
to shock onset (h)*
8.9 (2.1–28.0) 5.9 (1.6–19.5) 0.172
Highest total creatine
kinase (IU/L)*
1,034 (451–2545) 2,209 (733–4345) , 0.001
Highest creatine
kinase/ULN*
4.8 (2.0–9.9) 10.6 (3.3–20.3) , 0.001
Thrombolytic given 3.3% 40.9% 0.001
Left ventricular ejection
fraction (%)†
(n 5 52) (n 5 247) 0.995
30.3 6 12.6 30.0 6 12.6
*Median (interquartile range); other data presented as mean 6 SD or percentages.
†Measured on the same day as or after the onset of shock.
MI 5 myocardial infarction; ULN 5 upper limit of normal.
Table 3. Hemodynamic Characteristics† of Patients With
Predominant LV Failure
Non-ST-segment
Elevation
(n 5 152)
ST-segment
Elevation
(n 5 729)
p
Value
Heart rate (beats/min) 93.8 6 25.7 95.5 6 25.8 0.469
Systolic blood pressure
(mm Hg)
88.6 6 25.0 88.3 6 22.5 0.882
Diastolic blood pressure
(mm Hg)
51.6 6 17.2 53.0 6 17.3 0.397
Diastolic blood pressure
,50 mm Hg
35.4% 35.9% 1.000
Right-heart catheterization* 60.5% 65.2% 0.306
Cardiac output (L/min) (n 5 40) (n 5 235) 0.552
3.9 6 1.3 3.9 6 1.6
Cardiac index (L/min/m2) (n 5 67) (n 5 338) 0.961
2.0 6 0.7 2.1 6 0.8
PCWP (mm Hg) (n 5 83) (n 5 449) 0.700
24.0 6 9.9 23.6 6 8.4
Right atrial pressure
(mm Hg)
(n 5 48) (n 5 227) 0.104
12.5 6 6.6 14.6 6 7.5
Pulm. artery systolic
pressure (mm Hg)
(n 5 52) (n 5 289) 0.320
43.6 6 15.8 40.6 6 12.2
Pulm. artery diastolic
pressure (mm Hg)
(n 5 52) (n 5 291) 0.760
24.6 6 9.1 23.7 6 7.8
Data presented are mean 6 SD or percentages. *Right heart catheterization
performed on 92 non-ST-segment-elevation and 475 ST-segment-elevation patients.
†Measurements often obtained on vasopressor and intra-aortic balloon support.
PCWP 5 pulmonary capillary wedge pressure; pulm. 5 pulmonary.
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0.001), whereas the left anterior descending or right coro-
nary artery was affected less often in this group. Thrombol-
ysis In Myocardial Infarction flow grade and severity of the
culprit-artery stenosis were similar in the two groups.
In-hospital revascularization (Fig. 2). Angioplasty was
performed post shock less often in patients with non-ST-
segment elevation MI (17.8% vs. 34%, p 5 0.001), but more
of these patients underwent bypass surgery post shock
(21.1% vs. 13.4%, p 5 0.023). Thus, the overall rate of
revascularization was similar in both groups (36.8% vs.
41.9%).
In-hospital outcome. Ischemia tended to recur more often
in patients with non-ST-segment elevation than in patients
with ST-segment elevation MI (25.7% vs. 17.4%, p 5
0.058), although the proportion of patients experiencing
re-infarction was similar in the groups (6.4% vs. 8.5%).
In-hospital mortality also was similar: 62.5% for patients
with non-ST-segment elevation and 60.4% for patients
with ST-segment elevation MI (ST-segment elevation ver-
sus non-ST-segment elevation odds ratio (OR) for death
0.91, 95% confidence interval (CI) 0.64 to 1.31, p 5 0.649).
After multivariate adjustment for patient age and treatment
(intra-aortic balloon, thrombolytic therapy, coronary an-
giography, and bypass surgery) variables, the OR was in the
direction of a survival benefit for patients with non-ST-
segment elevation MI, but it remained non-significant (OR
1.30, 95% CI 0.83 to 2.02, p 5 0.252).
DISCUSSION
Non-ST-segment elevation MI. Cardiogenic shock con-
tinues to be the leading cause of death in patients hospital-
ized with acute MI (12). Moreover, despite a better under-
standing of the importance of timeliness in treatment and
advances in pharmacologic and mechanical reperfusion
therapies that have decreased overall mortality with MI
(1,7), the mortality associated with CS complicating acute
MI has remained relatively high (10–13). Recent reports
indicate a decreasing mortality over time with increasing
rates of revascularization (14). The randomized SHOCK
Trial revealed a trend toward lower mortality at 30 days, and
significantly lower mortality at six months, in patients with
MI treated with early revascularization (9). Therefore, it
becomes important to identify patients with CS who might
benefit from specific therapies.
Of patients presenting with acute MI, about 30% do not
have ST-segment elevation (1), and a recent report of an
international registry of patients in CS revealed that about
14% of patients with primary LV failure had non-ST-
segment elevation MI (10). In fact, the binary classification
system of acute MI has evolved from a pathological desig-
nation (transmural vs. subendocardial) to an ECG designa-
tion (Q wave vs. non-Q wave). However, the increased use
of reperfusion therapy has made the clinical distinction
between Q wave and non-Q wave MI less apparent. More
recently, the direction of ST-segment deviation during
acute infarction has been recognized to be a more powerful
predictor of clinical outcome than the presence or absence of
Q waves (4,15–17). It is also increasingly clear that the
pathogenesis, clinical course, prognosis and treatment of
patients presenting with non-ST-segment elevation MI
differ significantly from those of patients with ST-segment
elevation MI (18–20). The striking finding of this study is
the high rate of circumflex-artery occlusion as the culprit
lesion in patients with non-ST-segment elevation MI, who
also had more frequent prior MI and severe multivessel
disease. The misclassification of non-ST-segment elevation
as “nontransmural” MI leads to a failure to administer
reperfusion therapy in the group of patients with “posterior”
ST-segment elevation.
Patients with non-ST-segment elevation MI have smaller
infarcts (as shown by lower peak CK levels), earlier times to
peak CK, pathologic evidence of reperfusion, more subtotal
occlusions among those undergoing early angiography (21–
23), and more recurrent ischemia, compared with patients
who have ST-segment elevation MI (24–26). In addition,
clinical and demographic characteristics differ significantly
by the presence or absence of ST-segment elevation with
MI (20,27). Patients with non-ST-segment elevation MI
Figure 2. Rates of in-hospital coronary angiography and revascularization
after the diagnosis of CS caused by LV failure. CABG 5 coronary artery
bypass surgery; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 4. Angiographic Characteristics of the
Infarct-related Artery
Non-ST-segment
Elevation
ST-segment
Elevation
p
Value
Location (n) (52) (351) 0.001
Left anterior descending 36.5% 50.1%
Left circumflex 34.6% 13.4%
Right coronary 17.3% 30.2%
Left main 11.5% 6.3%
TIMI flow grade (n) (45) (320) 0.513*
0 or 1 66.7% 66.9%
2 26.7% 18.8%
3 6.7% 14.4%
Severity of stenosis (n) (51) (341) 0.494*
,50% 0.0% 0.6%
50% to 90% 17.7% 20.8%
.90% 82.4% 78.6%
*p value from Mantel-Haenszel test of linear trend.
TIMI 5 Thrombolysis in Myocardial Infarction.
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generally are older, are more often female, and have a higher
incidence of diabetes mellitus, hypertension, CHF and prior
MI. Furthermore, although early mortality with non-ST-
segment elevation MI is lower, the cumulative mortality at
one to two years is similar to that of patients with ST-
segment elevation, and patients with non-ST-segment ele-
vation MI have more recurrent ischemia and re-infarction
(20,25).
Clinical characteristics. By contrast, the characteristics
and outcome of patients with non-ST-segment elevation
MI in CS are less clear. In a recent analysis of the Global
Use of Strategies to Open Occluded Coronary Arteries
(GUSTO)-IIb trial, patients with non-ST-segment eleva-
tion MI in whom shock developed had a similar mortality
but different clinical and angiographic characteristics than
CS patients with ST-segment elevation MI (28). Similar to
that study, patients in the SHOCK Trial Registry with
non-ST-segment elevation MI were older and had a higher
incidence of comorbid factors, including CHF, renal insuf-
ficiency and peripheral vascular disease. There was a higher
incidence of prior MI and bypass surgery, compared with
patients having ST-segment elevation MI, although the
proportion of female patients was similar in each group. As
expected, patients with non-ST-segment elevation received
thrombolytic therapy less often than those with ST-segment
elevation MI. Yet, the total CK and the ratio of highest CK
to the upper limit of normal were lower in patients with
non-ST-segment elevation MI. Furthermore, in the smaller
subset of patients undergoing measurement of LV function,
ejection fraction was similar between groups. The smaller
infarcts in patients with non-ST-segment elevation MI may
compensate for their higher baseline risk, resulting in the
same mortality seen overall in the SHOCK Trial Registry.
Similarly, the smaller infarcts in the non-ST-segment ele-
vation group—compared with patients with ST-segment
elevation MI—despite having more prior infarctions, may
explain the similar LV function and hemodynamic measures
observed, including heart rate, filling pressures and cardiac
index values.
Angiographic characteristics. As reported in previous
studies, patients with non-ST-segment elevation MI had
more multivessel disease and, specifically, more triple-vessel
disease than did patients with ST-segment elevation MI
(22). It is interesting that the left circumflex was the culprit
artery significantly more often in patients with non-ST-
segment elevation than in patients with ST-segment eleva-
tion MI, and this finding has also been noted in the absence
of shock. Of note, most patients with acute MI whose ECG
is misclassified are those with acute circumflex or circumflex
obtuse marginal artery branch occlusion; infarction of the
high lateral or posterolateral walls of the LV may not be
detected on the standard 12-lead ECG (23,29). In this
setting, the lack of ST-segment elevation may be associated
with a total coronary occlusion or transmural (Q wave)
infarction. Therefore, patients with non-ST-segment eleva-
tion MI represent a heterogeneous group for whom appro-
priate reperfusion therapy may be withheld. This has
important implications, particularly in the setting of CS,
where pharmacologic or mechanical reperfusion therapy
may be indicated to prevent or treat shock.
In-hospital revascularization. The role of revasculariza-
tion for ST-segment elevation or new LBBB MI has
previously been evaluated (30–33) and has recently been
clarified (9). Emergency early revascularization resulted in a
significant reduction in six-month mortality in the random-
ized SHOCK Trial (9). In the SHOCK Trial Registry,
patients with non-ST-segment elevation MI underwent less
coronary angiography and less angioplasty after the onset of
CS, which was probably secondary to their higher-risk
profile and more multivessel disease, but they had similar
mortality compared with patients who had ST-segment
elevation MI. Similar to studies of non-ST-segment eleva-
tion MI patients without shock, we saw a trend toward
more recurrent ischemia in shock patients with non-ST-
segment elevation MI. Thus, early angiography and appro-
priate revascularization might reduce recurrent ischemia and
enhance outcome in this group of patients. However, the
absence of a benefit in patients older than 75 years of age
assigned to early revascularization in the SHOCK Trial
should be noted.
In-hospital outcome. Despite the smaller infarcts of pa-
tients with non-ST-segment elevation MI, their early mor-
tality was similar to that of patients with ST-segment
elevation. This may be a result of the higher-risk profile and
possible underuse of potentially beneficial therapies, such as
revascularization, in patients with non-ST-segment eleva-
tion MI. Alternatively, smaller infarcts and more viable
myocardium (as evidenced by more recurrent ischemia) may
work together to reduce mortality in this high-risk group. In
addition, perhaps in the setting of shock, traditional risk
factors for a poor outcome do not further affect mortality.
Study limitations. These data should be interpreted with
caution because potentially confounding factors influencing
mortality cannot be expected to be equally distributed
among the groups in this registry setting. In addition, we
could not separate the group with non-ST-segment eleva-
tion MI into those with ST-segment depression, those with
(possibly) old LBBB, or other subsets. Although these
ECG-defined groups of patients with MI have been shown
to have different features and prognoses, comparisons made
between the entire group of patients with non-ST-segment
elevation MI and those with ST-segment elevation MI
remain valid. Conclusions concerning hemodynamic data
and LV function should be made in view of the fact that
these parameters were available only on a limited number of
patients.
Conclusions. Compared with shock patients who had
ST-segment elevation MI, patients with non-ST-segment
elevation are older and are more likely to have comorbid
disease, prior infarctions and multivessel disease. In about
30% of these patients, the left circumflex is the culprit
artery, suggesting that a standard 12-ECG in these patients
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may show “posterior” elevation. Despite their higher-risk
profile, patients with non-ST-segment elevation MI and
CS had an in-hospital mortality rate similar to that of
patients with ST-segment elevation. The common occur-
rence of recurrent ischemia and the infrequent use of
angiography represent opportunities for earlier intervention,
which may enhance outcome. Early reperfusion therapy for
circumflex-artery occlusion should be considered when non-
ST-segment elevation MI causes CS.
Reprint requests and correspondence: Dr. Alice K. Jacobs,
Boston Medical Center, 88 East Newton St., Boston, Massachu-
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